Pfizer (PFE)

FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have be...

AstraZeneca stock crashed Thursday after its Ionis-partnered treatment for a rare heart disease failed in Phase 3 testing.

They may not remain cheap for too much longer.

A 7% dividend yield will grab your attention, but be sure to read the fine print.

Hospira brand bacteriostatic water is a sterile, non-pyrogenic preparation of water for injection that contains 0.9

Pfizer was downgraded to Hold as analysts cited delayed pipeline catalysts, management changes and reduced near-term re-rating potential.

One stands above the others.

Could this be the secret to Pfizer's rebound strategy?

Analysts have given Alnylam Pharmaceuticals an average price target of $436.

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

These stocks offer high yields, are big names in their respective sectors, and have strong fundamentals.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Zoetis (NYSE:ZTS) and its pee...

Maximize your investment opportunities in US stocks with a TFSA while being aware of the tax implications of dividends.

It could prove to be a case of better later than never for the healthcare giant.

Pharmaceutical companies are on an M&A spree that could break records this year as they look for novel drug and clinical-stage candidates to bolster the development pipeline.

Nike is set to report earnings on June 30. Here's what to expect.

AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.

Why settle for puny yields when you can buy these monster dividend stocks?

Things are going from bad to worse for the pharmaceutical giant.

Pfizer is deeply out of favor on Wall Street, which could be a huge opportunity for long-term dividend investors.